Female sex hormones are associated with the reduction of serum sodium and hypertension complications in patients with aldosterone-producing adenoma

Endocrine Journal

Volumn 60, Issue 11, 2013, Pages 1261-1268

  Lu, Zhao Hui ^a   Zhu, Xiao Xiao ^a   Tang, Zhi Qing ^a   Yang, Guo Qing ^a   Du, Jin ^a   Wang, Xian Ling ^a   Yang, Jin Zhi Ou ^a   Gu, Wei Jun ^a   Guo, Qing Hua ^a   Jin, Nan ^a   Yang, Li Juan ^a   Ba, Jian Ming ^a   Dou, Jing Tao ^a   Mu, Yi Ming ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Aldosterone producing adenoma; Gender; Menopause; Vascular complications

Indexed keywords

SEX HORMONE;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; BRAIN HEMORRHAGE; BRAIN INFARCTION; CHRONIC KIDNEY FAILURE; DISEASE ASSOCIATION; FEMALE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIMARY HYPERALDOSTERONISM; SEX DIFFERENCE; SODIUM BLOOD LEVEL;

ADENOMA; ADRENAL GLAND NEOPLASMS; ADRENALECTOMY; ALDOSTERONE; BIOLOGICAL MARKERS; CEREBROVASCULAR DISORDERS; CHINA; COMORBIDITY; FEMALE; GONADAL STEROID HORMONES; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MALE; MIDDLE AGED; POTASSIUM; RETROSPECTIVE STUDIES; SEX CHARACTERISTICS; SEX DISTRIBUTION; SEX FACTORS; SODIUM; VASCULAR DISEASES;

EID: 84888406173     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ13-0123     Document Type: Article

References (50)

1. Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, et al. (2003) Primary aldosteronism and hypertensive disease. Hypertens 42: 161-165.
2. Young WF Jr. (2003) Minireview: Primary aldosteronism-changing concepts in diagnosis and treatment. Endocrinology 144: 2208-2213.
3. Fogari R, Preti P, Zoppi A, Rinaldi A, Fogari E, et al. (2007) Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on the use of an aldosterone/renin ratio above 25 as a screening test. Hypertens Res 30: 111-117.
4. Ye D, Dong F, Lu X, Zhang Z, Feng Y, et al. (2012) Analysis of various etiologies of hypertension in patients hospitalized in the endocrinology division. Endocrine 42: 174-181.
5. Rossi GP, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P, et al. (2008) Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab 19: 88-90.
6. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, et al. (2008) Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 168: 80-85.
7. Quinkler M, Born-Frontsberg E, Fourkiotis VG (2010) Comorbidities in primary aldosteronism. Horm Metab Res 42: 429-434.
8. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, et al. (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45: 1243-1248.
9. Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, et al.; Participants of the German Conn's Registry (2009) Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab 94: 1125-1130.
10. Born-Frontsberg E, Reincke M, Beuschlein F, Quinkler M (2009) Participants of German Conn's Registry Tumor size of Conn's adenoma and comorbidities. Horm Metab Res 41: 785-788.
11. Sukor N (2012) Primary aldosteronism: from bench to bedside. Endocrine 41: 31-39.
12. Colyewright M, Reckelhoff JF, Ouyang P (2008) Menopause and hypertension: an age-old debate. Hypertension 51: 952-959.
13. Reckelhoff JF (2010) Maric CSex and gender differences in cardiovascular-renal physiology and pathophysiology. Steroids 75: 745-746.
14. Rosano GM, Vitale C, Marazzi G, Volterrani M (2007) Menopause and cardiovascular disease: the evidence. Climacteric 10: 19-24.
15. Wake R, Yoshiyama M (2009) Gender differences in ischemic heart disease. Recent Pat Cardiovasc Drug Discov 4: 234-240.
16. Silbiger S, Neugarten J (2008) Gender and human chronic renal disease. Gend Med 5: S3-S10.
17. Yang, XP, Reckelhoff JF (2011) Estrogen hormonal replacement therapy and cardiovascular disease. Curr Opin Nephrol Hypertens 20: 133-138.
18. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, et al.; Women's Health Initiative Investigators (2003) Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349: 523-534.
19. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, et al.; HERS Research Group (2002) Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288: 58-66.
20. Ferrari P, Shaw SG, Nicod J, Saner E, Nussberger J (2004) Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. J Hypertens 22: 377-381.
21. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, et al. (2004) Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 89: 1045-1050.
22. Chalmers J, MacMahon S, Mancia G, Whitworth J, Beilin L, et al. (1999) 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clin Exp Hypertens 21: 1009-1060.
23. Blacher J, Asmar R, Djane S, London GM, Safar ME (1999) Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 33: 1111-1117.
24. Sechi LA, Kronenberg F, De Carli S, Falleti E, Zingaro L, et al. (1997) Association of serum lipoprotein (a) levels and apolipoprotein (a) size polymorphism with tar-get-organ damage in arterial hypertension. JAMA 277: 1689-1695.
25. Sechi LA, Zingaro L, Catena C, De Marchi S (2000) Increased fibrinogen levels and hemostatic abnormalities in patients with arteriolar nephrosclerosis: association with cardiovascular events. Thromb Haemost 84: 565-557.
26. Yang D, Haines CJ, Pan P (2008) Menopausal symptoms in mid-life women in southern China. Climacteric 11: 329-936.
27. Brent GA (2008) Clinical practice. Graves' disease. N Engl J Med 358: 2594-2605.
28. Caturegli P, Newschaffer C, Olivi A, Pomper MG, Burger PC, Rose NR (2005) Autoimmune hypophysitis. Endocr Rev 26: 599-614.
29. Lafranchi SH, Snyder DB, Sesser DE, Skeels MR, Singh N, et al. (2003) Follow-up of newborns with elevated screening T4 concentrations. J Pediatr 143: 296-301.
30. Schirpenbach C, Segmiller F, Diederich S, Hahner S, Lorenz R, et al. (2009) The diagnosis and treatment of primary hyperaldosteronism in Germany: results on 555 patients from the German Conn Registry. Dtsch Arztebl Int 106: 305-311.
31. Tang KL, Yang CH, Li LM (2011) Retroperitoneal laparoscopic operation for aldosterone-producing adenomas: a report of 205 cases. Chin J Gen Pract 10: 583-585. (Article in Chinese) http://www.cqvip.com/ QK/85925X/201108/38872042.html
32. Liu Q, Li HZ, Zhou XF, Zhou YR, Zhu WL, Zeng ZP (2006) Clinical analysis of cardiac damage in patients with primary hyperaldosteronism (PA) caused by adenoma. Beijing Med J 28: 78-80. (Article in Chinese) http://new.med.wanfangdata.com.cn/Paper/ Detail?id=PeriodicalPaper_bjyx200602005
33. Zhang W, Tang ZY, Wang WQ, Ning G (2007) Prevalence of metabolic syndrome in patients with primary aldosteronism. Chin J Endocrinol Metab 23 (6): 532-534. (Article in Chinese) http://www.cqvip.com/ QK/91842X/200706/27738269.html
34. Li NF, Li HJ, Wang HM (2011) Clinical analysis of 330 patients with primary aldosteronism. Chin J Endocrinol Metab 27: 752-754. (Article in Chinese) http://d.wanfangdata. com.cn/Periodical_zhnfmdx201109013.aspx
35. Arias-Loza PA, Hu K, Dienesch C, Mehlich AM, König S, et al. (2007) Both estrogen receptor subtypes, α and β, attenuate cardiovascular remodeling in aldosterone salt-treated rats. Hypertension 50: 432-438.
36. Xue BJ, Badaue-Passos D Jr., Guo F, Gomez-Sanchez CE, Hay M, et al. (2009) Sex differences and central protective effect of 17β-estradiol in the development of aldosterone/NaCl-induced hypertension. Am J Physiol Heart Circ Physiol 296: H1577-H1585.
37. Vasan RS, Evans JC, Benjamin EJ, Levy D, Larson MG, et al. (2004) Relations of serum aldosterone to cardiac structure: Gender-related differences in the Framingham Heart Study. Hypertension 43: 957-962.
38. Berardelli R, Karamouzis I, D'Angelo V, Zichi C, Fussotto B, et al. (2013) Role of mineralocorticoid receptors on the hypothalamus-pituitary-adrenal axis in humans. Endocrine 43: 51-58.
39. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, et al. (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45: 1243-1248.
40. Dahl LK, Love RA (1954) Evidence for relationship between sodium (chloride) intake and human essential hypertension. AMA Arch Intern Med 94: 525-531.
41. Sasaki N (1964) The relationship of salt intake to hypertension in the Japanese. Geriatrics 19: 735-744.
42. Swaye PS, Gifford Jr RW, Berrettoni JN (1972) Dietary salt and essential hypertension. Am J Cardiol 29: 33-38.
43. Stamler J (1997) The INTERSALT study: background, methods, findings, and implications. Am J Clin Nutr 65: 626S-642S.
44. He FJ, MacGregor GA (2002) Effect of modest salt reduction on blood pressure: meta analysis of randomized trials. Implication for public health. J Hum Hypertens 16: 761-770.
45. Stachenfeld NS, Taylor HS (2009) Sex hormone effects on body fluid and sodium regulation in women with and without exercise-associated hyponatremia. J Appl Physiol 107: 864-872.
46. Stachenfeld NS, Keefe DL (2002) Estrogen effects on osmotic regulation of AVP and fluid balance. Am J Physiol Endrocrinol Metab 283: E711-E721.
47. Fraser CL, Sarnacki P (1989) Na+-K+-ATPase pump funciton in rat brain synaptosomes is different in males and females. Am J Physiol 257: E284-E289.
48. Letavernier E, Peyrard S, Amar L, Zinzindohoué F, Fiquet B, et al. (2008) Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma. J Hypertens 26: 1816-1823.
49. Zarnegar R, Young WF Jr, Lee J, Sweet MP, Kebebew E, et al. (2008) The aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. Ann Surg 247: 511-518.
50. Rossi GP, Bolognesi M, Rizzoni D, Seccia TM, Piva A, et al. (2008) Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension 51: 1366-1371.